琥珀酸美托洛尔缓释片联合曲美他嗪治疗冠心病心绞痛的效果研究  

Effect of metoprolol succinate sustained-release tablets combined with trimetazidine in the treatment of angina pectoris of coronary heart disease

作　　者：霍海伟 Huo Haiwei(Department of Pharmacy,Luohe Third People’s Hospital,Luohe 462000,China)

机构地区：[1]漯河市第三人民医院药剂科,漯河462000

出　　处：《中国实用医刊》2025年第4期82-85,共4页Chinese Journal of Practical Medicine

摘　　要：目的探讨琥珀酸美托洛尔缓释片联合曲美他嗪对冠心病心绞痛(CHD-AP)的治疗效果。方法队列研究。抽取2021年1月至2023年12月漯河市第三人民医院收治的CHD-AP患者68例,按随机数字表法分为单药组和联合组,每组34例。单药组采用常规治疗+琥珀酸美托洛尔缓释片治疗,联合组在单药组治疗基础上联合曲美他嗪治疗。比较两组治疗效果、心功能指标[左心室舒张早期最大血流/二尖瓣心房收缩期最大血流(E/A)、短轴缩短率(FS)、左室射血分数(LVEF)]、西雅图心绞痛量表(SAQ)评分及不良反应发生情况。结果联合组CHD、AP治疗总有效率(94.12%,32/34;91.18%,31/34)均高于单药组(73.53%,25/34;70.59%,24/31),P均<0.05。治疗后,联合组E/A、FS、LVEF及SAQ各项评分均高于单药组(P均<0.05)。两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论琥珀酸美托洛尔缓释片联合曲美他嗪治疗CHD-AP,可以更好地提高其临床疗效,促进心功能改善,提升SAQ评分,且不会增加不良反应发生风险。ObjectiveTo investigate the therapeutic effect of metoprolol succinate sustained-release tablets combined with trimetazidine on angina pectoris of coronary heart disease(CHD-AP).MethodsA total of 68 patients with CHD-AP admitted to Luohe Third People’s Hospital from January 2021 to December 2023 were selected for the cohort study,and they were divided into the single drug group and the combined group according to random number table method,with 34 cases in each group.The single drug group was treated with conventional treatment+metoprolol succinate sustained release tablets,and the combined group was treated with trimetazidine based on the treatment of the single drug group.The therapeutic effect,cardiac function indexes including left ventricular early diastolic maximum blood flow/mitral atrial systolic maximum blood flow(E/A),fractional shortening(FS)and left ventricular ejection fraction(LVEF),Seattle angina questionnaire(SAQ)score and adverse reactions were compared between the two groups.ResultsThe total effective rates of CHD and AP in the combined group(94.12%,32/34;91.18%,31/34)were higher than those in the single drug group(73.53%,25/34;70.59%,24/31);all P<0.05.After treatment,the E/A,FS,LVEF and each item-score of SAQ in the combined group were higher than those in the single drug group(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).ConclusionsMetoprolol succinate sustained-release tablets combined with trimetazidine in the treatment of CHD-AP can better improve clinical efficacy,promote the improvement of cardiac function,raise SAQ score,and will not increase the risk of adverse reactions.

关 键 词：冠心病 心绞痛 琥珀酸美托洛尔缓释片 曲美他嗪 心功能 

分 类 号：R541.4[医药卫生—心血管疾病]